1. Albumin-based drug delivery: harnessing nature to cure disease
- Author
-
Kenneth A. Howard, Matthias Kuhlmann, Michael Lykke Hvam, and Maja Thim Larsen
- Subjects
0301 basic medicine ,Drug ,Economics and Econometrics ,Half-life extension ,media_common.quotation_subject ,Genetic enhancement ,Review ,Biology ,Pharmacology ,03 medical and health sciences ,0302 clinical medicine ,Neonatal Fc receptor ,Materials Chemistry ,Media Technology ,Neonatal Fc receptor (FcRn) ,Albumin-binding ,media_common ,Albumin fusions ,Human serum albumin (HSA) ,Targeted drug delivery ,Molecular medicine ,Albumin ,Drugs ,Forestry ,Intracellular delivery ,Transport protein ,030104 developmental biology ,030220 oncology & carcinogenesis ,Drug delivery - Abstract
The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic levels, however, challenges such as rapid renal clearance, degradation or non-specific accumulation requires drug delivery enabling technologies. Albumin is a natural transport protein with multiple ligand binding sites, cellular receptor engagement, and a long circulatory half-life due to interaction with the recycling neonatal Fc receptor. Exploitation of these properties promotes albumin as an attractive candidate for half-life extension and targeted intracellular delivery of drugs attached by covalent conjugation, genetic fusions, association or ligand-mediated association. This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.
- Published
- 2015
- Full Text
- View/download PDF